

# Supplementary Material: Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas.

Maximilian Gassenmaier, Matthias Hahn, Gisela Metzler, Jürgen Bauer, Amir Sadegh Yazdi, Ulrike Keim, Claus Garbe, Nikolaus Benjamin Wagner and Stephan Forchhammer

**Table S1.** Clinicopathologic characteristics of the cases.

Characteristics	Metastasizing Melanoma ( <i>n</i> = 35) <i>n</i> (%)	Non-Metastasizing Melanoma ( <i>n</i> = 35) <i>n</i> (%)	Severely Dysplastic Compound Nevus ( <i>n</i> = 35) <i>n</i> (%)	<i>p</i> -Value MM vs. NMM	<i>p</i> -Value SDN vs. Melanoma
Breslow thickness (mean, range)	0.7 mm (0.3–1.0)	0.7 mm (0.4–1.0)	n.a.	0.91	n.a.
Age (mean, range)	62 years (31–91)	61 years (30–86)	45 years (20–70)	0.95	<0.001
Gender					
Female	14 (40.0%)	14 (40.0%)	15 (42.9%)	1.0	0.84
Male	21 (60.0%)	21 (60.0%)	20 (57.1%)		
Site					
Head and neck	10 (28.6%)	10 (28.6%)	2 (5.7%)	1.0	0.005
Trunk	14 (11.4%)	14 (11.4%)	25 (71.4%)		
Upper extremities	4 (11.4%)	4 (11.4%)	1 (2.9%)		
Lower extremities	7 (20%)	7 (20%)	7 (20%)		
Subtype					
Superficial spreading	25 (71.4%)	23 (65.7%)	n.a.	0.42	n.a.
Lentigo maligna	6 (17.1%)	10 (28.6%)	n.a.		
Acral lentiginous	2 (5.7%)	1 (2.9%)	n.a.		
Nevoid	2 (5.7%)	0 (0%)	n.a.		
Spitzoid	0 (0%)	1 (2.9%)	n.a.		
Regression					
Present	18 (51.4%)	15 (42.9%)	0 (0%)	0.63	<0.001
Absent	17 (48.6%)	20 (57.1%)	35 (100%)		
Ulceration					
Present	4 (11.4%)	2 (5.7%)	0 (0%)	0.67	0.18
Absent	31 (88.6%)	33 (94.3%)	35 (100%)		
Stage					
III	14 (40.0%)	0 (0%)	n.a.	<0.001	n.a.
IV	21 (60.0%)	0 (0%)	n.a.		
Follow-up (mean, range)	65 months (5–139)	99 months (31–153)	92 months (31–141)	<0.001	0.23

Abbreviations: MM, metastasizing melanoma. n.a., not applicable. NMM, non-metastasizing melanoma. SDN, severely dysplastic compound nevus.